ANTX vs INSM vs JPM

For growth investors, Insmed Incorporated (INSM) is the stronger pick with 66.

7% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate AN2 Therapeutics, Inc. (ANTX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Insmed Incorporated (INSM) delivered a total return of +226.

5%, compared to -69. 2% for AN2 Therapeutics, Inc. (ANTX). Over 10 years, the gap is even starker: INSM returned +845. 4% versus ANTX's -39. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AN2 Therapeutics, Inc.

(ANTX) is the lower-risk stock at 0. 42β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately 123% more volatile than ANTX relative to the S&P 500. On balance sheet safety, Insmed Incorporated (INSM) carries a lower debt/equity ratio of 104% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Insmed Incorporated (INSM) is pulling ahead at 66.

7% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: AN2 Therapeutics, Inc. grew EPS 32. 6% year-over-year, compared to -15. 1% for Insmed Incorporated. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -210. 5% for Insmed Incorporated — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -194. 0% for INSM. At the gross margin level — before operating expenses — INSM leads at 79. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for INSM: 111.

0% to $206. 50.

In this comparison, JPM (1.

9% yield) pays a dividend. ANTX, INSM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Insmed Incorporated (INSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), +845. 4% 10Y return). Both have compounded well over 10 years (INSM: +845. 4%, ANTX: -39. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ANTX (Healthcare) and INSM (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ANTX is a small-cap quality compounder stock; INSM is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ANTX, INSM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.